Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,038

Document Document Title
WO/2019/126253A8
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/143508A1
Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.  
WO/2019/141096A1
Provided is a substituted urea compound, and a preparation method and use thereof. More particularly, the invention relates to a substituted urea compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorphic substance, a ...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/110521A1
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...  
WO/2019/104011A1
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...  
WO/2019/099307A1
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...  
WO/2019/084383A1
The invention provides a compound of formula (I): (Formula (I)) or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a cryst...  
WO/2019/079626A1
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by...  
WO/2019/040106A3
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040105A3
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/031618A8
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/040105A2
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/038656A1
The present invention relates to parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid. The present invention also relates to process of preparing such formulations.  
WO/2019/040106A2
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040107A1
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.  
WO/2019/036384A1
The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as can...  
WO/2019/031618A1
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/021140A1
The present technology relates to molecules that stimulate the immune system for use in treating drug abuse and addiction, and to the methods of synthesis thereof. Said molecules comprise a calixarene chemical structure, preferably calix...  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2018/235813A1
A compound represented by the formula, which has an RORĪ³t inhibiting effect and is useful as a prophylactic or therapeutic agent for autoimmune diseases, allergic diseases, etc., or a salt thereof.  
WO/2018/168643A1
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...  
WO/2018/154596A1
Provided herein is a process for synthesis of tiotropium bromide wherein the coupling of scopine with 2, 2-dithienyl glycolate is achieved by a two step process under mild conditions.  
WO/2018/151678A1
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...  
WO/2018/145216A1
An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage fo...  
WO/2018/124001A1
The present invention pertains to novel, exceptional low-molecular compounds that specifically antagonize the BMP signaling pathway, and because these compounds can be used to modulate cell growth, differentiation, proliferation, and apo...  
WO/2018/115591A1
Compounds of formula (I) wherein R1, R2,R3,R4,R5,R23,R24,L, A and Bare as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1(...  
WO/2018/084817A3
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/084817A2
The present invention relates to a new crystalline form of an active agent, the preparation processes of said crystalline form, the pharmaceutical compounds containing said crystalline form and the use of said compounds in the treatment ...  
WO/2018/083101A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/083103A1
The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for p...  
WO/2018/055642A1
Provided herein is a process for synthesis of tiotropium bromide and a process for synthesis of scopine starting from a dimethyl tartarate compound. The synthetic sequence comprises a double Mannich reaction (Robinson-Schopf reaction).  
WO/2018/057596A1
A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, te...  
WO/2018/031434A1
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.  
WO/2018/009017A1
The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composit...  
WO/2017/216159A1
The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.  
WO/2017/212425A1
The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as define...  
WO/2017/201468A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2017/197177A1
In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of compound C41 to a subject in need th...  
WO/2017/193951A1
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.  
WO/2017/189822A1
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compos...  
WO/2017/179976A1
The invention relates to improved means and methods for N- dealkylation of alkylated amines. Provided is a method for the catalytic N- dealkylation of an N-alkylated amine substrate, comprising incubating said amine substrate in a suitab...  
WO/2017/165822A1
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...  
WO/2017/165822A8
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...  
WO/2017/148519A1
The invention relates to new heteroaryl derivatives of the formula wherein X 1 is selected from the group consisting of: N and CH; X 2 is selected from the group consisting of: N and CF; (whith the proviso that at least one of X1 and X2 ...  
WO/2017/144978A1
Proposed are a salt of tesofensine with optically-active acetylamino acids, and a method for producing same. The invention also relates to pharmaceutical compositions including a salt of tesofensine with optically-active acylamino acids ...  
WO/2017/141927A1
The present invention provides a compound represented by formula [I'], which has the effect of inhibiting an enzyme which produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I']: the structure represented by for...  
WO/2017/138896A1
The present invention relates to a new crystalline form of an active agent, the processes for preparing this crystalline form, the pharmaceutical compositions comprising this crystalline form and the use of these compositions in the trea...  
WO/2017/123542A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1 and ...  
WO/2017/102091A1
The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...  

Matches 1 - 50 out of 3,038